Skip to content

Clinical diagnosis and treatment model of nasopharyngeal carcinoma patients based on the characteristic changes of peripheral circulating cell immune function

Clinical diagnosis and treatment model of nasopharyngeal carcinoma patients based on the characteristic changes of peripheral circulating cell immune function

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500103195
Enrollment
Unknown
Registered
2025-05-26
Start date
2025-06-02
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal cancer

Interventions

Healthy Group:None
Benign nasal disease group:None

Sponsors

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1: Healthy group: Individuals aged 18-80 years old who experience physical examination with normal blood routine, urine routine, liver function biochemical indexes, renal function biochemical indexes, and cardiac enzyme spectrum biochemical indexes. 2: Nasopharyngeal carcinoma group: 18-80 years old, pathologically confirmed, untreated patients. 3: Benign nasopharyngeal disease group: patients with benign nasopharyngeal diseases who have symptoms such as epistaxis, nasal discharge with blood, nasal congestion, rhinitis, sinusitis, nasopharyngeal mass, tinnitus, deafness, headache, etc, 18-80 years old, with clear diagnosis results.

Exclusion criteria

Exclusion criteria: 1: Healthy group: use immune-related drugs within 6 months; have autoimmune diseases; have tumors or abnormal tumor markers; abnormal electrolyte biochemical indicators. 2: Nasopharyngeal carcinoma group: patients with autoimmune diseases or more than two types of tumors. 3: Benign nasopharyngeal disease group: patients with nasopharyngeal carcinoma who have been diagnosed and treated in the past; patients taking immunosuppressants; patients whose source is not traceable or whose basic information is incomplete; diagnostic information is incomplete.

Design outcomes

Primary

MeasureTime frame
Immune-related indicators ;Objective response rate;

Secondary

MeasureTime frame
Epstein-Barr virus-related indicators ;Disease-free survival ;Overall survival ;

Countries

China

Contacts

Public ContactCui Wei

Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

wendycuiwei@sina.com+86 135 2018 7626

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026